ClinicalTrials.Veeva

Menu

Efficacy and Safety Study of Subcutaneous Secukinumab in Treatment of Subjects With Moderate to Severe Chronic Plaque-type Psoriasis as Compared to Etanercept and Placebo.

Novartis logo

Novartis

Status and phase

Withdrawn
Phase 3

Conditions

Psoriasis

Treatments

Biological: Intervention B
Biological: Intervention A
Biological: Placebo

Study type

Interventional

Funder types

Industry

Identifiers

NCT01900782
2013-000463-83 (EudraCT Number)
CAIN457A2314

Details and patient eligibility

About

This withdrawn study was to assess the safety and efficacy of secukinumab compared to etanercept and placebo in patients who have moderate to severe, chronic, plaque-type psoriasis.

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Chronic plaque-type psoriasis, moderate to severe
  • Candidate for systemic therapy defined as having psoriasis not adequately controlled by: topical treatment, phototherapy and/or previous systemic therapy

Exclusion criteria

  • Forms of psoriasis other than chronic plaque-type
  • Ongoing use of treatments not allowed for psoriasis

Other protocol-defined inclusion/exclusion criteria may apply

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Triple Blind

0 participants in 4 patient groups, including a placebo group

Dosing Regimen 1
Experimental group
Description:
Subcutaneous injection
Treatment:
Biological: Intervention A
Active Comparator
Active Comparator group
Description:
Subcutaneous injection
Treatment:
Biological: Intervention B
Placebo
Placebo Comparator group
Description:
Subcutaneous injection
Treatment:
Biological: Placebo
Dosing Regimen 2
Experimental group
Description:
Subcutaneous injection
Treatment:
Biological: Intervention A

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems